Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Practical Radiation Oncology
|
February 11, 2018
Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: Defining clinically relevant endpoints
Tobias R Chapman, Stephen R Bowen, Stephanie K Schaub, et al.
Investigational New Drugs
|
June 22, 2026
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study
William P Harris, Pilar García-Alfonso, Jean Phillipe Metges, et al.
Plos One
|
September 9, 2014
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes
Ryan R Gordon, Mengchu Wu, Chung-Ying Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2016
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
Sunil R Hingorani, William P Harris, J Thaddeus Beck, et al.
Cancers
|
February 13, 2026
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001
Elena Gabriela Chiorean, Sheela R Damle, David B Zhen, et al.
Hepatology (Baltimore, Md.)
|
November 10, 2025
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma
Anthony B El-Khoueiry, Richard D Kim, William P Harris, et al.
JCO Oncology Practice
|
December 15, 2025
Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Amy H Huang, Gin Yi Lee, Chuan Angel Lu, et al.
British Journal of Cancer
|
November 14, 2018
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2017
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R Hingorani, Lei Zheng, Andrea J Bullock, et al.
The Oncologist
|
September 20, 2022
KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
Adam C Diehl, Lindsay M Hannan, David B Zhen, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Practical Radiation Oncology
|
February 11, 2018
Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: Defining clinically relevant endpoints
Tobias R Chapman, Stephen R Bowen, Stephanie K Schaub, et al.
Investigational New Drugs
|
June 22, 2026
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study
William P Harris, Pilar García-Alfonso, Jean Phillipe Metges, et al.
Plos One
|
September 9, 2014
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes
Ryan R Gordon, Mengchu Wu, Chung-Ying Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2016
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
Sunil R Hingorani, William P Harris, J Thaddeus Beck, et al.
Cancers
|
February 13, 2026
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001
Elena Gabriela Chiorean, Sheela R Damle, David B Zhen, et al.
Hepatology (Baltimore, Md.)
|
November 10, 2025
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma
Anthony B El-Khoueiry, Richard D Kim, William P Harris, et al.
JCO Oncology Practice
|
December 15, 2025
Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Amy H Huang, Gin Yi Lee, Chuan Angel Lu, et al.
British Journal of Cancer
|
November 14, 2018
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2017
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R Hingorani, Lei Zheng, Andrea J Bullock, et al.
The Oncologist
|
September 20, 2022
KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
Adam C Diehl, Lindsay M Hannan, David B Zhen, et al.
Page
of 4